BidaskClub downgraded shares of Aduro BioTech (NASDAQ:ADRO) from a strong-buy rating to a buy rating in a research note issued to investors on Friday, April 6th.
A number of other brokerages also recently issued reports on ADRO. ValuEngine upgraded Aduro BioTech from a strong sell rating to a sell rating in a research note on Wednesday, March 14th. Oppenheimer dropped their price target on Aduro BioTech from $15.00 to $13.00 and set an outperform rating for the company in a research note on Wednesday, December 13th. HC Wainwright dropped their price target on Aduro BioTech from $18.00 to $9.50 and set a buy rating for the company in a research note on Wednesday, December 13th. Canaccord Genuity set a $30.00 price target on Aduro BioTech and gave the stock a buy rating in a research note on Thursday, December 14th. Finally, Zacks Investment Research downgraded Aduro BioTech from a buy rating to a hold rating in a research report on Wednesday, March 7th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $14.50.
Shares of NASDAQ:ADRO opened at $7.20 on Friday. Aduro BioTech has a fifty-two week low of $5.82 and a fifty-two week high of $14.05.
In other news, insider Stephen T. Isaacs sold 40,000 shares of the firm’s stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $8.91, for a total transaction of $356,400.00. Following the transaction, the insider now owns 245,746 shares in the company, valued at $2,189,596.86. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Stephen T. Isaacs sold 72,051 shares of the firm’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $8.48, for a total value of $610,992.48. Following the sale, the insider now directly owns 231,380 shares in the company, valued at approximately $1,962,102.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 118,925 shares of company stock worth $1,011,936. Insiders own 6.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of ADRO. Bank of New York Mellon Corp boosted its holdings in Aduro BioTech by 23.9% in the third quarter. Bank of New York Mellon Corp now owns 175,642 shares of the biotechnology company’s stock worth $1,871,000 after acquiring an additional 33,843 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Aduro BioTech in the third quarter worth about $167,000. Trexquant Investment LP purchased a new position in shares of Aduro BioTech in the third quarter worth about $175,000. Wells Fargo & Company MN raised its stake in shares of Aduro BioTech by 111.5% in the third quarter. Wells Fargo & Company MN now owns 72,854 shares of the biotechnology company’s stock worth $776,000 after purchasing an additional 38,415 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Aduro BioTech by 5.5% in the third quarter. Schwab Charles Investment Management Inc. now owns 174,478 shares of the biotechnology company’s stock worth $1,859,000 after purchasing an additional 9,140 shares during the last quarter. 44.91% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Aduro BioTech (NASDAQ:ADRO) Lowered to Buy at BidaskClub” was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://weekherald.com/2018/04/16/bidaskclub-lowers-aduro-biotech-adro-to-buy.html.
About Aduro BioTech
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.